Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35


Use of administrative data to increase the practicality of clinical trials: Insights from the Women's Health Initiative.

Anderson GL, Burns CJ, Larsen J, Shaw PA.

Clin Trials. 2016 Oct;13(5):519-26. doi: 10.1177/1740774516656579.


Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity.

Kim DJ, Roh E, Lee MH, Oi N, Lim do Y, Kim MO, Cho YY, Pugliese A, Shim JH, Chen H, Cho EJ, Kim JE, Kang SC, Paul S, Kang HE, Jung JW, Lee SY, Kim SH, Reddy K, Yeom YI, Bode AM, Dong Z.

Cancer Res. 2016 Mar 1;76(5):1146-57. doi: 10.1158/0008-5472.CAN-15-0442.


Anti-androgenic effects of flavonols in prostate cancer.

Boam T.

Ecancermedicalscience. 2015 Oct 22;9:585. doi: 10.3332/ecancer.2015.585. Review.


Molecular cancer prevention: Current status and future directions.

Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET.

CA Cancer J Clin. 2015 Sep-Oct;65(5):345-83. doi: 10.3322/caac.21287. Review.


Prevention and early detection of prostate cancer.

Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A.

Lancet Oncol. 2014 Oct;15(11):e484-92. doi: 10.1016/S1470-2045(14)70211-6. Review.


Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217).

Gritz ER, Arnold KB, Moinpour CM, Burton-Chase AM, Tangen CM, Probstfield JF, See WA, Lieber MM, Caggiano V, Moody-Thomas S, Szczepanek C, Ryan A, Carlin S, Hill S, Goodman PJ, Padberg RM, Minasian LM, Meyskens FL, Thompson IM Jr.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1638-48. doi: 10.1158/1055-9965.EPI-14-0202.


Prevention of prostate cancer: outcomes of clinical trials and future opportunities.

Thompson I Jr, Kristal A, Platz EA.

Am Soc Clin Oncol Educ Book. 2014:e76-80. doi: 10.14694/EdBook_AM.2014.34.e76. Review.


Future directions in the prevention of prostate cancer.

Thompson IM Jr, Cabang AB, Wargovich MJ.

Nat Rev Clin Oncol. 2014 Jan;11(1):49-60. doi: 10.1038/nrclinonc.2013.211. Review.


Survival in the prostate cancer prevention trial.

Tangen CM, Goodman PJ, Thompson IM Jr.

N Engl J Med. 2013 Nov 14;369(20):1968. doi: 10.1056/NEJMc1311498. No abstract available.


Preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice.

Opoku-Acheampong AB, Unis D, Henningson JN, Beck AP, Lindshield BL.

PLoS One. 2013 Oct 18;8(10):e77738. doi: 10.1371/journal.pone.0077738.


Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle.

Berruti A, Vignani F, Russo L, Bertaglia V, Tullio M, Tucci M, Poggio M, Dogliotti L.

Open Access J Urol. 2010 Jul 23;2:109-24. Review.


Long-term survival of participants in the prostate cancer prevention trial.

Thompson IM Jr, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG.

N Engl J Med. 2013 Aug 15;369(7):603-10. doi: 10.1056/NEJMoa1215932.


Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study.

Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P.

BMJ. 2013 Jun 18;346:f3406. doi: 10.1136/bmj.f3406.


Current status of 5α-reductase inhibitors in prostate disease management.

Kang DI, Chung JI.

Korean J Urol. 2013 Apr;54(4):213-9. doi: 10.4111/kju.2013.54.4.213.


Association between biomarkers of obesity and risk of high-grade prostatic intraepithelial neoplasia and prostate cancer--evidence of effect modification by prostate size.

Fowke JH, Motley S, Dai Q, Concepcion R, Barocas DA.

Cancer Lett. 2013 Jan 28;328(2):345-52. doi: 10.1016/j.canlet.2012.10.010.


Health-related quality-of-life findings for the prostate cancer prevention trial.

Moinpour CM, Darke AK, Donaldson GW, Cespedes D, Johnson CR, Ganz PA, Patrick DL, Ware JE Jr, Shumaker SA, Meyskens FL, Thompson IM Jr.

J Natl Cancer Inst. 2012 Sep 19;104(18):1373-85.


Testosterone replacement and prostate cancer.

Ramasamy R, Fisher ES, Schlegel PN.

Indian J Urol. 2012 Apr;28(2):123-8. doi: 10.4103/0970-1591.98449.


Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials.

Pinsky PF, Black A, Grubb R, Crawford ED, Andriole G, Thompson I, Parnes H.

Cancer. 2013 Feb 1;119(3):593-601. doi: 10.1002/cncr.27774.


Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.

Kristal AR, Till C, Tangen CM, Goodman PJ, Neuhouser ML, Stanczyk FZ, Chu LW, Patel SK, Thompson IM, Reichardt JK, Hoque A, Platz EA, Figg WD, Van Bokhoven A, Lippman SM, Hsing AW.

Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1823-32. doi: 10.1158/1055-9965.EPI-12-0695.

Items per page

Supplemental Content

Support Center